'In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo'

https://www.nejm.org/doi/full/10.1056/NEJMoa2306963?query=featured_homeo